Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya

被引:1
|
作者
Lobin, Christopher [1 ]
Orang'o, Elkanah Omenge [2 ,3 ]
Were, Edwin [2 ]
Muthoka, Kapten [2 ]
Singh, Kavita [4 ,5 ]
De Allegri, Manuela [4 ]
Obermann, Konrad [6 ]
Doeberitz, Magnus von Knebel [1 ]
Bussmann, Hermann [1 ]
机构
[1] Heidelberg Univ Hosp, Inst Pathol, Appl Tumor Biol, Heidelberg, Germany
[2] Moi Univ, Coll Hlth Sci, Sch Med, Dept Reprod Hlth, Eldoret, Kenya
[3] Aga Khan Univ, Dept Obstet & Gynaecol, Nairobi, Kenya
[4] Heidelberg Univ Hosp, Heidelberg Inst Global Hlth, Heidelberg, Germany
[5] Publ Hlth Fdn India, New Delhi, India
[6] Ruprecht Karls Univ Heidelberg, CPD Ctr Prevent Med & Digital Hlth, Heidelberg, Germany
基金
美国国家卫生研究院;
关键词
cervical cancer screening; cost-effectiveness analyses; dual staining; HPV DNA test; visual inspection with acetic acid; HUMAN-PAPILLOMAVIRUS INFECTION; VISUAL INSPECTION; ACETIC-ACID; CYTOLOGY; TRIAGE;
D O I
10.1002/ijc.35036
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While the incidence of cervical cancer has dropped in high-income countries due to organized cytology-based screening programs, it remains the leading cause of cancer death among women in Eastern Africa. Therefore, the World Health Organization (WHO) now urges providers to transition from widely prevalent but low-performance visual inspection with acetic acid (VIA) screening to primary human papillomavirus (HPV) DNA testing. Due to high HPV prevalence, effective triage tests are needed to identify those lesions likely to progress and so avoid over-treatment. To identify the optimal cost-effective strategy, we compared the VIA screen-and-treat approach to primary HPV DNA testing with p16/Ki67 dual-stain cytology or VIA as triage. We used a Markov model to calculate the budget impact of each strategy with incremental quality-adjusted life years and incremental cost-effectiveness ratios (ICER) as the main outcome. Deterministic cost-effectiveness analyses show that the screen-and-treat approach is highly cost-effective (ICER 2469 Int$), while screen, triage, and treat with dual staining is the most effective with favorable ICER than triage with VIA (ICER 9943 Int$ compared with 13,177 Int$). One-way sensitivity analyses show that the results are most sensitive to discounting, VIA performance, and test prices. In the probabilistic sensitivity analyses, the triage option using dual stain is the optimal choice above a willingness to pay threshold of 7115 Int$ being cost-effective as per WHO standards. The result of our analysis favors the use of dual staining over VIA as triage in HPV-positive women and portends future opportunities and necessary research to improve the coverage and acceptability of cervical cancer screening programs. In its updated screening recommendations for cervical cancer, the World Health Organization has urged existing programs to use visual inspection with acetic acid (VIA) as a primary screening tool to transition to human papillomavirus (HPV) DNA testing. This study shows that primary HPV testing plus triage with either dual-stain cytology or VIA performs better than VIA screening alone in detecting precancerous lesions in low-resource settings, with dual-stain cytology being the most cost-effective triage option. Furthermore, the results indicate the feasibility of equipping laboratories in low-resource settings with sophisticated technologies and operating them cost-effectively. image
引用
收藏
页码:1257 / 1267
页数:11
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada
    Cromwell, I.
    Gaudet, M.
    Peacock, S. J.
    Aquino-Parsons, C.
    BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [32] A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe
    Sun, Li
    Patel, Shruti
    Fiorina, Camilla
    Glass, Audrey
    Rochaix, Lise
    Foss, Anna M.
    Legood, Rosa
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (05): : 829 - 844
  • [33] Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests
    Kulasingam, Shalini L.
    Myers, Evan R.
    Lawson, Herschel W.
    McConnell, K. John
    Kerlikowske, Karla
    Melnikow, Joy
    Washington, A. Eugene
    Sawaya, George F.
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (02): : 321 - 328
  • [34] The cost-effectiveness of alternative vision screening models among preschool children in rural China
    Wang, Lei
    Congdon, Nathan
    Hogg, Ruth E.
    Zhang, Siqi
    Li, Mengjie
    Shi, Yaojiang
    Jin, Ling
    He, Fei
    Wang, Huan
    Boswell, Matthew
    Iyer, Mony
    ACTA OPHTHALMOLOGICA, 2019, 97 (03) : E419 - E425
  • [35] Cost-effectiveness of cervical cancer screening: Comparison of screening policies
    van den Akker-van Marle, ME
    van Ballegooijen, M
    van Oortmarssen, GJ
    Boer, R
    Habbema, JDF
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (03): : 193 - 204
  • [36] The cost-effectiveness of osteoporosis screening strategies for postmenopausal women
    Nayak, S.
    Greenspan, S. L.
    Liu, H.
    Michaud, K.
    Owens, D. K.
    Roberts, M. S.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 : 410 - 411
  • [37] COST-EFFECTIVENESS OF ALTERNATIVE SCREENING STRATEGIES FOR DEVELOPMENTAL DYSPLASIA OF THE HIP
    ROSENDAHL, K
    MARKESTAD, T
    LIE, RT
    SUDMANN, E
    GEITUNG, JT
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1995, 149 (06): : 643 - 648
  • [38] COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING PROGRAM IN CHINA
    Zhou, D.
    Liu, Z.
    Wang, W.
    Zhao, M.
    Tang, W.
    Gong, F.
    VALUE IN HEALTH, 2022, 25 (07) : S377 - S377
  • [39] CERVICAL-CANCER SCREENING - ATTENDANCE AND COST-EFFECTIVENESS
    KOOPMANSCHAP, MA
    VANOORTMARSSEN, GJ
    VANAGT, HMA
    VANBALLEGOOIJEN, M
    HABBEMA, JDF
    LUBBE, KTN
    INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (03) : 410 - 415
  • [40] Modeling Cost-Effectiveness of Cervical Cancer Screening in Hungary
    Voko, Zoltan
    Nagyjanosi, Laszlo
    Margitai, Barnabas
    Koevi, Rita
    Toth, Zoltan
    Laszlo, Daniel
    Kalo, Zoltan
    VALUE IN HEALTH, 2012, 15 (01) : 39 - 45